Biotech Startups

Lemna Labs develops natural active and functional ingredients derived from duckweed for use in cosmetic and personal care formulations. The company focuses on plant-based innovation combining efficacy, sustainability, and supply chain independence.

1 investor

Frazier-founded precision oncology company developing CNS-penetrant inhibitors; acquired by Blueprint Medicines in 2021.

1 investor

LenioBio develops ALiCE, a cell-free protein expression platform that accelerates the discovery, development, and manufacturing of proteins and biologics for pharmaceutical and vaccine manufacturers. The platform addresses production bottlenecks in drug and vaccine development by enabling faster, scalable biomanufacturing beyond traditional cell-based approaches.

1 investor

LensGen is an ophthalmic medical device company that has developed Juvene, a curvature-changing fluid-optic intraocular lens designed to treat cataracts and presbyopia. The biomimetic lens is placed in the position of the eye's natural lens and adjusts its dioptric power using the eye's own muscle contractions.

1 investor

Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.

1 investor

Lepu Biopharma is a Chinese biopharmaceutical company that develops antibody-drug conjugates (ADCs) and other oncology drugs, including the CD20-targeting ADC MRG001 for relapsed/refractory diffuse large B-cell lymphoma. Its candidate drugs undergo clinical trials and regulatory review by China's National Medical Products Administration.

1 investor

LePure Biotech provides integrated bioprocessing solutions for the biopharmaceutical industry, including single-use systems, cell culture, filtration and purification, and GMP cleanroom contamination control. It serves drug manufacturers from early-stage research through commercial production across protein biologics, vaccines, cell and gene therapies, and small-molecule drugs.

1 investor

Leucadia Therapeutics is developing Arethusta, a first-in-class outpatient treatment for Alzheimer's disease, initially aiming to reverse mild cognitive impairment associated with the condition before targeting prevention and cure. The company operates in the biotech and neurological therapeutics space.

1 investor

Leucid Bio develops CAR-T cell therapies based on a proprietary Lateral CAR platform that redesigns the CAR structure to mimic the lateral signalling arrangement of natural immune receptors. The technology, derived from 20 years of research led by Dr John Maher at King's College London, aims to increase T-cell potency and durability while reducing toxicity.

1 investor

Levation Pharma is a pharmaceutical company developing LEV-102, a topical oxymetazoline-based gel for treating acquired blepharoptosis (drooping upper eyelids). The product is in a Phase I/II clinical trial in the U.S. and is not yet approved for sale.

1 investor

Lever VC is a venture capital firm focused on alternative protein and sustainable food and agriculture. The firm's investment team has deployed over $500 million and executed over 100 deals since 2014, backed by in-house scientific and technical expertise in bioengineering, materials science, and synthetic biology.

1 investor

Levur engineers sustainable oils through microbial fermentation to replace unsustainable plant and animal oils in food and cosmetic products. The company addresses deforestation and habitat destruction caused by conventional palm oil production.

1 investor

Levya uses precision fermentation with wild, non-GMO yeasts to produce fats and oils that replicate the fatty acid profiles of cocoa butter, palm oil, and shea butter. The company supplies these fermentation-derived ingredients to the food and cosmetics industries as alternatives to conventional fats.

1 investor

Lex Diagnostics develops in vitro diagnostic assays, including point-of-care molecular diagnostics, immunodiagnostics, and antimicrobial susceptibility testing. It works on assay development, reagent chemistry, and manufacturing transfer for regulated diagnostic products.

1 investor

Lexicon Pharmaceuticals develops and commercializes pharmaceutical products, including the marketed drug INPEFA and drug candidates in clinical development such as sotagliflozin, pilavapadin, and LX9851, serving patients in need of treatments across various therapeutic areas.

1 investor

LGC Group provides life sciences, diagnostics, and analytical products and services, including measurement standards, components, and testing solutions. It works with the scientific community on applications such as disease diagnosis, precision medicine, food safety, and environmental protection.

1 investor

Lgem builds patented tubular photobioreactor (PBR) systems for industrial cultivation of autotrophic algae, offering automated, modular systems ranging from 25 to over 1,000,000 litres. It also operates the AlgaeHUB facility where customers can test and validate algae production processes at industrial scale before investing, serving researchers and industry professionals.

1 investor

Liberate Bio develops lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies and genetic medicines, with a focus on myeloid-optimized CAR-M programs that target tissues beyond the liver. The company works on targeted nucleic acid delivery for therapeutic applications.

1 investor

Licella is a developer of hydrothermal liquefaction technology that converts low-cost waste biomass into advanced biofuels, including sustainable aviation fuel (SAF), renewable diesel, and biomaterials. The company operates commercial-scale facilities globally and partners with energy, chemical, and aerospace companies to decarbonize transport and industrial sectors.

1 investor

LICORbio develops fluorescent imaging instruments for scientific research, including systems for 2D and 3D sample imaging with multiple detection channels. Its technology builds on fluorescent imaging methods first developed in 2001 and is aimed at scientists who require accurate imaging data.

1 investor

LifeAnalytics develops and sells web applications for life science, medical, and industrial R&D, offering IAS, a cloud-based integrated analysis platform that unifies imaging, NGS, flow cytometry, mass spectrometry, and molecular structure data into a single workflow for analysis, review, and reporting. It also provides AI-for-science implementation services (generative AI, RAG, local LLMs, AI agents, and research data infrastructure) and contract data analysis services for research use.

1 investor

LifeCellsNI provides cord blood and stem cell extraction and cryogenic storage services for individuals and families, alongside laboratory rentals with GMP-grade processing for researchers, biotech companies, and clinical trials. It operates a biobanking facility serving Northern Ireland and Ireland.

1 investor

Life Science Connect is a B2B media and community platform serving the life sciences and environmental markets, combining industry-focused content, professional communities, and audience insights to help brands reach specialized professionals. The company operates events, digital content platforms, and advisory services built by leaders with deep backgrounds in life sciences publishing and industry operations.

1 investor

Fierce Life Sciences provides news, analysis, and event education for the biopharma and life sciences industry, covering stages from preclinical research through market. It serves senior-level decision makers through editorial content and both virtual and live events.

1 investor